KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Return on Sales (2019 - 2025)

Historic Return on Sales for Esperion Therapeutics (ESPR) over the last 7 years, with Q3 2025 value amounting to 0.37%.

  • Esperion Therapeutics' Return on Sales rose 2400.0% to 0.37% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.35%, marking a year-over-year decrease of 2100.0%. This contributed to the annual value of 0.01% for FY2024, which is 18300.0% up from last year.
  • According to the latest figures from Q3 2025, Esperion Therapeutics' Return on Sales is 0.37%, which was up 2400.0% from 0.16% recorded in Q2 2025.
  • Over the past 5 years, Esperion Therapeutics' Return on Sales peaked at 0.42% during Q1 2024, and registered a low of 11.4% during Q1 2021.
  • Its 5-year average for Return on Sales is 2.3%, with a median of 1.78% in 2023.
  • Per our database at Business Quant, Esperion Therapeutics' Return on Sales surged by 313300bps in 2021 and then plummeted by -24600bps in 2022.
  • Esperion Therapeutics' Return on Sales (Quarter) stood at 4.48% in 2021, then skyrocketed by 33bps to 3.02% in 2022, then surged by 41bps to 1.78% in 2023, then skyrocketed by 83bps to 0.3% in 2024, then dropped by -22bps to 0.37% in 2025.
  • Its Return on Sales was 0.37% in Q3 2025, compared to 0.16% in Q2 2025 and 0.64% in Q1 2025.